Quolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseasesPosted by On

BOSTON–(BUSINESS WIRE)– #ANXIETY–Quolet, a private clinical stage biopharmaceutical company, is announcing the completion of a Phase 1 healthy volunteer study evaluating pure Cannabidiol (CBD) (clinicaltrials.gov NCT05032807). CBD is approved for treatment-resistant epilepsy in children, and recent trials suggest that it may be useful for treating other disorders, such as schizophrenia and anxiety. However, oral CBD has relatively poor bioavailability. Researchers at King’s College London partnered wit

Source link


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.